AI3 Bio, Inc. raised $0 (Watertown, MA)

LIVE PUBLIC DATA Source: SEC EDGAR Form D filings (U.S. Securities and Exchange Commission) · Last refreshed: Thu, 05 Nov 2026 08:45:31 GMT

AI3 Bio, Inc. plus every comparable record, with all columns and source links, as one CSV.

Not investment advice and not an offer or solicitation to buy or sell any security.

58 / 100 vendor spend propensity

Estimated post-raise budget for CPA / Tax / Audit services: $0 (heuristic)

  • Operating company: new capital typically funds hiring, facilities and vendors.
  • No amount sold reported yet.
  • Healthcare & Life Sciences companies are a strong fit for CPA / Tax / Audit services.
  • New filing (not an amendment): the raise is fresh.
  • Filed 2 days ago.
FieldValue
IndustryBiotechnology (Healthcare & Life Sciences)
Operating companyYes
Exemption506(b)
Amount sold$0
Total offeringIndefinite / n/a
Investors so far7
First sale2026-06-09
Filed2026-11-04
EntityCorporation

Executives and related persons (from the filing)

  • Steven Altschuler: Executive Officer, Director
  • Michael Lyman: Executive Officer
  • Nick Seaver: Executive Officer, Director
  • Fabian Tenenbaum: Director
  • Jeanne Cunicelli: Director
  • Alan Ezekowitz: Director
  • Jonathan Kagan: Executive Officer

View the filing on SEC EDGAR

Markdown version

AI3 Bio, Inc. vs. top 3 peers

OrganizationLocationCapital raisedRecord date
AI3 Bio, Inc.Watertown2026-11-04
Tru Singular Health, Inc.Natick$1,000,0002026-10-30
XRHealth, Inc.Needham$16,253,0292026-10-23
511 Therapeutics, Inc.Cambridge$500,0002026-10-30

Related records

Newly funded companies in Massachusetts (SEC Form D) Newly funded Healthcare & Life Sciences companies (SEC Form D)

Get new raises like this every morning

FormDPulse emails you newly funded companies that match your ideal customer profile.

See plans

Often used together

Or get the Advisor Prospecting Bundle for $14.99 one-time: Full CSV unlock of newly funded companies plus a grant readiness pack.